세레스 테라퓨틱스MCRB 주가

[144] 144

♻️ 재탕[4] 내부자 거래 — 4

♻️ 재탕[4] 내부자 거래 — 4

♻️ 재탕[4] 내부자 거래 — 4

[4] 내부자 거래 — 4

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

CAMBRIDGE, Mass., May 12, 2026 -- Seres Therapeutics, Inc. , a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual BioConnect...

Seres Therapeutics: Q1 Earnings Snapshot

CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Seres Therapeutics Inc. on Tuesday reported a loss of $19.9 million in its first quarter. On a per-share basis, the Cambridge, Massachusetts-based...

Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the analyst consensus estimate of $(1.88) by 10.64 percent. This is a 155.47 percent decrease over earnings of $3.75 per share

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live...

[10-Q] 분기 실적 — 10-Q